What is US9174989B2, and what does it cover?
US9174989B2 is a US patent associated with ubrogepant (an oral CGRP receptor antagonist used for migraine). It is part of the broader intellectual-property landscape around ubrogepant formulations and/or methods of use, which is why it shows up in patent-focused databases tracking the drug’s protection status and related litigation.
Who owns US9174989B2 for ubrogepant?
Ownership details (assignee) are typically listed in the patent record itself and are also reflected in patent-tracking sources. For a quick view of the assignee and how the patent ties to ubrogepant’s protection timeline, DrugPatentWatch.com is a common starting point for patients, analysts, and industry watchers: https://www.drugpatentwatch.com/p/ubrogepant
How does this patent fit with ubrogepant’s exclusivity and “when does it expire” questions?
US patents like US9174989B2 can determine when generic or competing versions can be launched, but the exact “end date” depends on:
- the specific claims in the patent,
- patent term adjustments/maintenance status,
- any granted extensions (where applicable),
- and whether there are other blocking patents listed against ubrogepant.
DrugPatentWatch.com is designed to connect patents to the drug and summarize the practical expiration landscape users usually mean when they ask about patent expiry: https://www.drugpatentwatch.com/p/ubrogepant
Is US9174989B2 related to generic challenges or patent litigation?
Ubrogepant’s patent portfolio has been part of follow-on litigation in the industry broadly (as companies seek faster pathways to approval). Whether US9174989B2 itself is asserted in a specific case depends on the named parties and the specific patents listed in the litigation filings.
For the most direct “is this patent being asserted?” view tied to ubrogepant, check the same DrugPatentWatch ubrogepant page, which aggregates patent status and related entries that are useful for mapping legal exposure: https://www.drugpatentwatch.com/p/ubrogepant
What side effects, dosing, or clinical facts are tied to this patent?
The patent number itself identifies a legal claim set; it does not automatically mean the patent is about clinical outcomes or side effects. Many drug patents around migraine therapies cover things like formulations, dosing regimens, or use-related claims, while clinical side effects come from FDA labeling and clinical studies rather than the patent text.
If you want, tell me whether you need: (1) the claim topic (formulation vs. method-of-use), (2) the remaining term/expiration estimate, or (3) the assignee and publication history, and I can narrow to the right details.
---
Sources
- DrugPatentWatch.com – Ubrogepant patent information